ALEC ALECTOR

Alector Added to the NASDAQ Biotechnology Index

Alector Added to the NASDAQ Biotechnology Index

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 23, 2019.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index (SM) Fund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit .

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit .

Contacts

Media:

1AB

Dan Budwick, 973-271-6085

Investors:

Alector, Inc.

EN
20/12/2019

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Bus...

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. “Neil has...

December 12, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the Bank of America CNS Therapeutics Confere...

Alector to Participate in the Bank of America CNS Therapeutics Conference SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors ...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports Third Quarter 2025 Financial Results and Provides Busi...

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing toward IND-enabling studies Advancing ABC-enabled Tau, Alpha Synuclein and NLRP3 siRNA programs targeting peripheral delivery of novel therapies for neurodegenerative disorders Independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) in ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Announces Topline Results from Latozinemab Phase 3 Trial in In...

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In the 96-week, dou...

October 21, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Host Virtual Research and Development Event Highlighting PG...

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs --Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates-- SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company’s progranulin (PGRN) franchise and ...

September 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch